Sage Therapeutics' drug candidate SAGE-217 has been granted fast-track designation by the FDA as a treatment for major depressive disorder. The company has an ongoing midstage clinical development study of the drug, including four trials for movement and mood disorders.
FDA fast-tracks depressive disorder drug from Sage
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.